Biologics in Polymyositis and Dermatomyositis-Associated Interstitial Lung Disease

被引：6
|
作者：
Sun, Yuechi [1 ]
He, Yan [1 ]
Liu, Yuan [1 ]
Shi, Guixiu [1 ]
机构：
[1] Xiamen Univ, Dept Rheumatol, Affiliated Hosp 1, Xiamen 361003, Peoples R China
来源：
CURRENT PHARMACEUTICAL BIOTECHNOLOGY | 2014年 / 15卷 / 06期
关键词：
Biologics; dermatomyositis; interstitial lung disease; polymyositis; IL-1 RECEPTOR ANTAGONIST; ANTI-SYNTHETASE SYNDROME; INFLAMMATORY MYOPATHIES; RITUXIMAB TREATMENT; THERAPY; ADULT; MYOSITIS; EFFICACY; MODEL;
D O I：
10.2174/138920101506140910145940
中图分类号：
Q5 [生物化学]; Q7 [分子生物学];
学科分类号：
071010 ; 081704 ;
摘要：
Interstitial lung disease (ILD) is one of the most common complications of polymyositis (PM) and dermatomyositis (DM). It is always progressive and does not respond to conventional immunosuppressive agent treatment. Biologics are commonly used in treatment of rheumatic diseases. They are also used in polymyositis and dermatomyositis associated interstitial lung disease. This review will focus on the updated use of biologics in PM/DM-ILD.
引用
收藏
页码：521 / 524
页数：4
相关论文
共 50 条
  • [31] Increased Levels of Complement and Immunoglobulins in Dermatomyositis-associated Interstitial Lung Disease
    Zaizen, Yoshiaki
    Okamoto, Masaki
    Azuma, Kouichi
    Fukuoka, Junya
    Hoshino, Tomoaki
    EUROPEAN RESPIRATORY JOURNAL, 2024, 64
  • [32] Interstitial lung disease in polymyositis/dermatomyositis [Interstitielle Lungenkrankheit bei Polymyositis/Dermatomyositis]
    Schnabel A.
    Zeitschrift für Rheumatologie, 2013, 72 (3) : 220 - 226
  • [33] Interstitial lung disease in polymyositis and dermatomyositis.
    Marie, I
    Dominique, S
    Rémy-Jardin, M
    Hatron, PY
    Hachulla, E
    REVUE DE MEDECINE INTERNE, 2001, 22 (11): : 1083 - 1096
  • [34] INTERSTITIAL LUNG-DISEASE IN POLYMYOSITIS AND DERMATOMYOSITIS
    SONGCHAROEN, S
    RAJU, SF
    PENNEBAKER, JB
    JOURNAL OF RHEUMATOLOGY, 1980, 7 (03) : 353 - 360
  • [35] Interstitial lung disease in polymyositis and dermatomyositis.
    Schnabel A.
    Hellmich B.
    Gross W.L.
    Current Rheumatology Reports, 2005, 7 (2) : 99 - 105
  • [36] Survival benefit associated with early cyclosporine treatment for dermatomyositis-associated interstitial lung disease
    Dong Jin Go
    Jin Kyun Park
    Eun Ha Kang
    Hyun Mi Kwon
    Yun Jong Lee
    Yeong Wook Song
    Eun Bong Lee
    Rheumatology International, 2016, 36 : 125 - 131
  • [37] Interstitial lung disease in patients with polymyositis and dermatomyositis
    Falaus, S
    Damian, L
    Lazar, N
    Rednic, S
    Bolosiu, HD
    ANNALS OF THE RHEUMATIC DISEASES, 2005, 64 : 256 - 256
  • [38] Clinical nomogram assisting in discrimination of juvenile dermatomyositis-associated interstitial lung disease
    Minfei Hu
    Chencong Shen
    Fei Zheng
    Yun Zhou
    Liping Teng
    Rongjun Zheng
    Bin Hu
    Chaoying Wang
    Meiping Lu
    Xuefeng Xu
    Respiratory Research, 24
  • [39] Ykl-40 Is A Useful Biomarker For Evaluating Disease Activity And Predicting Prognosis In Patients With Polymyositis/dermatomyositis-Associated Interstitial Lung Disease
    Hozumi, H.
    Fujisawa, T.
    Kono, M.
    Suzuki, Y.
    Karayama, M.
    Furuhashi, K.
    Enomoto, N.
    Inui, N.
    Nakamura, Y.
    Suda, T.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2017, 195
  • [40] RISK FACTORS FOR RECURRENCE OF POLYMYOSITIS/DERMATOMYOSITIS ASSOCIATED INTERSTITIAL LUNG DISEASE
    Nakazawa, M.
    Kaneko, Y.
    Takeuchi, T.
    ANNALS OF THE RHEUMATIC DISEASES, 2016, 75 : 541 - 541
12345